Please login to the form below

Not currently logged in
Email:
Password:

Orencia

This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.

Pfizer closes on EU approval of lung cancer drug Vizimpro

Pfizer closes on EU approval of lung cancer drug Vizimpro

Bristol-Myers Squibb’s Orencia (abatacept) was backed as a second-line treatment for moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients (2 years and older), and

Latest news

More from news
Approximately 8 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept)  . 245. Athersys/ Healios. Licence. Development and commercialisation

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    Orencia and Actemra for rheumatoid arthritis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • BMS’ Brian Daniels to retire BMS’ Brian Daniels to retire

    Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics